Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

Prajwal Dhakal; Jasleen Kaur; Krishna Gundabolu; Vijaya Raj Bhatt

doi:10.1080/10428194.2019.1641802

$Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?$

Journal article

Open access

Peer reviewed

Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

Prajwal Dhakal, Jasleen Kaur, Krishna Gundabolu and Vijaya Raj Bhatt

Leukemia & lymphoma, Vol.61(1), pp.7-17

01/02/2020

DOI: 10.1080/10428194.2019.1641802

PMCID: PMC7261514

PMID: 31317803

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/7261514View

Open Access

Abstract

Recently, immunotherapeutic agents such as inotuzumab ozogamicin (INO), blinatumomab (BLIN), and tisagenlecleucel (TISA) have been approved for treatment of relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). No head to head trials have compared these agents. Thus, various factors influence the decision to choose an appropriate treatment for R/R ALL. INO may be preferred in patients with high tumor burden; BLIN is preferred in patients with low tumor burden or to eradicate minimal residual disease (MRD). Both INO and BLIN, compared to standard chemotherapy, increase the probability of receiving subsequent hematopoietic stem cell transplant (HSCT). TISA, approved for patients ≤25 years of age, is effective regardless of tumor burden or prior receipt of HSCT and can be used as a definite treatment in some patients. Further studies comparing the efficacy, safety, and other outcomes related to different immunotherapeutic options in combination with other treatment modalities and among themselves are needed.

blinatumomab

immunotherapy

inotuzumab ozogamicin

Relapsed/refractory acute lymphoblastic leukemia

tisagenlecleucel

Details

Title: Subtitle: Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
Creators: Prajwal Dhakal - University of Nebraska Medical Center
Jasleen Kaur - Hurley Medical Center
Krishna Gundabolu - University of Nebraska Medical Center
Vijaya Raj Bhatt - University of Nebraska Medical Center
Resource Type: Journal article
Publication Details: Leukemia & lymphoma, Vol.61(1), pp.7-17
DOI: 10.1080/10428194.2019.1641802
PMID: 31317803
PMCID: PMC7261514
NLM abbreviation: Leuk Lymphoma
ISSN: 1042-8194
eISSN: 1029-2403
Publisher: Taylor & Francis
Grant note: P30 CA036727 / National Cancer Institute 1 U54 GM115458 / National Institute of General Medical Sciences
Language: English
Date published: 01/02/2020
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359786702771

Metrics

17 Record Views

5 Times Cited - Web of Science